Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study.
Danielle Novetsky FriedmanPamela J GoodmanWendy M LeisenringLisa R DillerSusan L CohnRebecca M HowellSusan A SmithEmily S TonorezosSuzanne L WoldenJoseph P NegliaKirsten K NessTodd M GibsonPaul C NathanLucie M TurcotteBrent R WeilLeslie L RobisonKevin C OeffingerGregory T ArmstrongCharles A SklarTara O HendersonPublished in: Journal of the National Cancer Institute (2024)
Survivors of high-risk disease treated in the early days of risk stratification carry a markedly elevated burden of late recurrence, SMN, and organ-related multimorbidity, whereas survivors of low/intermediate-risk disease have a modest risk of late adverse outcomes.